Nissan Motor Company Limited

Eisai R&d Management Co., Ltd.

Harvard College

Kabushiki Kaisha Toshiba

Nec Corporation

Pioneer Corporation

Sony Ericsson Mobile Communications Japan, Inc.

Hisamitsu Pharmaceutical Company, Inc.

Ken Ito

Kazutaka Adachi

Akira Sawada

Hiroyuki Komatsu

Takashi Nakajima

Yuji Katsumata

Yoshito Kishi

Kazunobu Kira

Taketoshi Kawabe

Tohru Takahashi

Fukashi Sugasawa

Naohiko Inoue

Yoshiki Yasuno

Takeshi Fujishiro

Hiroyuki Ashizawa

Sadahiro Takahashi

Taketosi Kawabe

Yoshimasa Sakamoto

Junji Matsui

Yoichi Ozawa

Takaaki Karikomi

Kishan Agarwala

Kentaro Ueda

Yu Kato

Toshiaki Hirano

Masahiko Katayama

Masaki Tsuchida

Yusuke Adachi

Takanori Abe

Yuya Nakazawa

Takeshi Kokura

Sho Tachino

Katsuhisa Suzuki

Kana Hoshino

Akira Watanabe

Naruhito Higo

Akira Higashimata

Shinichiro Joe

Munetoshi Ueno

Junsuke Kuroki

Yoshinori Yamamura

Hideo Ito

Tetsuro Tateishi

Kengo Fujiwara

Junji Tsutsumi

Hideki Sudo

Haruhisa Tsuchikawa

Akio Kawai

Tsuyoshi Yamanaka

Taiichi Onoyama

Jun Motosugi

Yuichiro Saito

Hideo Iwamoto

Tadashi Okuda

Terumasa Hidaka

Hidehiko Sugita

Kazuyuki Kouno

Shou Oono

Tsuneo Konishi

Sadahiro Takakashi

Takashi Fujishiro

The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.

Macrocyclic compound and uses thereof

The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.

Macrocyclic compounds and uses thereof

The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof. 

The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof. 

A control device for electric motor vehicle uses the motor as the traveling driving source. The control device for electric motor vehicle is configured to decelerate by the regenerative braking force from the motor. The control device for electric motor vehicle is configured to detect the amount of the accelerator operation, detect the motor rotation speed proportionate to the traveling speed of the electric motor vehicle, and calculate the motor rotation speed estimated value according to the state of the electric motor vehicle. Additionally, the control device for electric motor vehicle is configured to detect or estimate the resistance component unrelated to the gradient from the vehicle state and correct the motor rotation speed estimated value according to the resistance component. Further, the control device for electric motor vehicle is configured to calculate the feedback torque to stop the electric motor vehicle based on the motor rotation speed and calculate the feedforward torque to compensate the feedback torque based on the corrected motor rotation speed estimated value. The control device for electric motor vehicle is configured to calculate the motor torque command value and control the motor based on the calculated motor torque command value. When the amount of the accelerator operation is equal to or less than the predetermined value and the electric motor vehicle is just before the stop of the vehicle, the motor torque command value is converged to 0 based on the feedback torque and the feedforward torque together with the reduction in the traveling speed.

Control device for electric motor vehicle and control method for electric motor vehicle

A control device for electric motor vehicle using the motor as the traveling driving source and configured to decelerate by a regenerative braking force from the motor detects the accelerator operation amount, calculates the disturbance torque estimated value, and detects or estimates the resistance component unrelated to the gradient from the vehicle state. The control device for electric motor vehicle corrects the disturbance torque estimated value according to the detected or estimated resistance component unrelated to the gradient. The motor is controlled on the basis of the motor torque command value. When the accelerator operation amount is equal to or less than the predetermined value and the electric motor vehicle is just before the stop of the vehicle, the motor torque command value converges to the corrected disturbance torque estimated value in conjunction with the reduction of the rotation speed of the motor.

The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.

Anti human Notch4 antibody

The device that generates the friction braking force to decelerate the vehicle estimates the disturbance torque acting on the vehicle. When the accelerator operation amount is equal to or less than the predetermined value and the vehicle is just before the stop of the vehicle, the control device for vehicle causes the friction braking amount to converge to the friction braking amount to the value decided on the basis of the disturbance torque estimated value Td in conjunction with the reduction in the motor rotation speed (speed parameter) proportionate to the traveling speed of the vehicle.

Control device for vehicle and control method for vehicle

The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof. 

A control device for electric motor vehicle using a motor as a traveling drive source and configured to decelerate by a regenerative braking force of the motor includes a motor torque command value setter configured to set a first torque target value for traveling based on the vehicle information as a motor torque command value for traveling based on the vehicle information before a speed parameter proportional to a traveling speed of an electric motor vehicle becomes equal to or less than a predetermined value, and set a second torque target value for stopping the electric motor vehicle and maintaining a vehicle stopped state as the motor torque command value when the speed parameter becomes equal to or less than the predetermined value, a motor controller configured to control the motor on the basis of the motor torque command value.

A control device for electric motor vehicle is configured to decelerate by a regenerative braking force of the motor when an accelerator operation amount decreases or becomes zero. The control device detects the accelerator operation amount, calculates a motor torque command value, and controls the motor on the basis of the motor torque command value calculated. The control device detects a speed parameter proportional to a traveling speed and calculates a feedback torque for stopping the vehicle on the basis of the speed parameter detected. The control device also estimates a disturbance torque acting on the motor and converges, as the speed parameter is reduced, the motor torque command value to the disturbance torque on the basis of the feedback torque when the accelerator operation amount decreases or becomes zero and the electric motor vehicle stops shortly. The control device adjusts the feedback torque according to the disturbance torque.

A control device for electric motor vehicle configured to decelerate by a regenerative braking force of the motor detects an accelerator operation amount, calculates a motor torque command value and controls the motor on the basis of the calculated motor torque command value. Further, a speed parameter proportional to a traveling speed is detected, and a feedback torque for stopping the electric motor vehicle is calculated on the basis of the detected speed parameter. Furthermore, the speed parameter is estimated in accordance with a state of the electric motor vehicle, and a feedforward torque is calculated on the basis of the estimated speed parameter. When accelerator operation amount is not larger than a predetermined value and the electric motor vehicle stops shortly, the motor torque command value is converged to zero on the basis of the feedback torque and the feedforward torque with a reduction in the traveling speed.

A motor control device of a vehicle includes a motor and a lock mechanism for locking the rotation of vehicle wheels. The motor control device includes a detection device for detecting release of the lock mechanism, a damping control device for suppressing torsional vibration of a drive shaft, and a current control device for controlling current flowing to the motor on the basis of a motor torque command value set by the damping control device. The current control device channels an excitation current for generating a magnetic flux in the motor on the basis of the detection result of the detection device.

Motor control device and motor control method

Growing community of inventors

Kanagawa, Japan

Ken Ito